Allopurinol is typically started at a low dose of 100 mg per day and gradually increased until your uric acid level drops below a target, usually around 6 mg/dL. The drug works by blocking the enzyme that produces uric acid, and the slow-and-steady approach to dosing is not just convention but a safety measure that reduces the risk of serious side effects. Getting the dose, timing, and monitoring right makes a real difference in whether the treatment works and whether you tolerate it well.
How Allopurinol Works
Uric acid is the end product of purine metabolism in your body. An enzyme called xanthine oxidase handles the final conversion step. Allopurinol blocks that enzyme, so less uric acid gets produced in the first place.1PubMed Central. Allopurinol for pain relief: more than just crystal clearance? Once uric acid levels stay low long enough, the monosodium urate crystals that have built up in your joints gradually dissolve. That crystal clearance is what eventually stops gout flares and, over time, shrinks tophi (the hard lumps of urate deposits some people develop).
Your body converts allopurinol into an active metabolite called oxypurinol, which does most of the ongoing work. Oxypurinol has a long half-life, which is why a single daily dose is usually enough to keep uric acid levels suppressed around the clock.
Starting Dose and How Titration Works
Nearly every guideline recommends starting at no more than 100 mg daily. If you have kidney problems, the starting dose may be even lower. The reason for starting low is straightforward: jumping straight to a higher dose raises the risk of a dangerous allergic reaction called allopurinol hypersensitivity syndrome, and a high starting dose is one of the clearest risk factors for that reaction.2JAMA Internal Medicine. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan
From that starting point, your doctor should check your uric acid level every few weeks and increase the dose in 100 mg steps until you reach target. In one study, roughly two-thirds of patients hit their target uric acid level after just a single 100 mg increase, and 97% of patients who were up-titrated eventually reached target, with a median final dose of 300 mg daily.3PubMed. Up-titration of allopurinol in patients with gout Some people need doses of 400, 500, or occasionally even higher, and that is fine as long as the increases are gradual and monitored. The key insight is that the starting dose matters for safety, but the maintenance dose should be whatever it takes to get your uric acid below target.
When to Take It
Allopurinol can be taken with or without food, and time of day does not meaningfully affect how well it works. Most people take it once daily, often in the morning, but there is no pharmacological reason why evening would be worse. The important thing is consistency: pick a time, take it every day, and do not skip doses.
One exception involves people on dialysis. During a hemodialysis session, roughly 40 to 57% of oxypurinol gets cleared from the blood, which means a dose taken before dialysis loses much of its effect. For that reason, patients on hemodialysis should take allopurinol after their session.4Journal of Nephrology. Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review
Expect Flares Early On, and Plan for Them
One of the most frustrating aspects of starting allopurinol is that it can actually trigger gout flares in the first weeks or months. This happens because as uric acid levels shift, crystals that were stable in your joints start to dissolve and shed, provoking an inflammatory response. Many people interpret this as the drug making things worse and stop taking it, which is understandable but counterproductive.
Colchicine taken alongside allopurinol during the first six months of treatment significantly reduces the frequency and severity of these startup flares.5PubMed. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis Low-dose anti-inflammatory drugs are sometimes used for the same purpose. Your doctor should discuss flare prophylaxis before you start, and if they do not, it is worth asking. The flares during initiation are not a sign the drug is failing. They are, paradoxically, a sign that crystal stores are being disturbed on the way to being eliminated.
Why You Should Not Stop Taking It
Allopurinol is a long-term, often lifelong medication. If you stop, your uric acid levels climb back to pre-treatment levels within weeks, and gout flares tend to return. A systematic review found relapse rates of 36 to 81% after stopping, with recurrences appearing anywhere from one to four and a half years out.6PubMed Central. Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review In one of the included studies, people who had lower uric acid levels both before and after stopping had better odds of staying flare-free, but for most people, stopping means the gout comes back.
Adherence makes a measurable difference. In a five-year follow-up study, patients in the lowest adherence group were far more likely to have flares in the past year (about a third) compared with those in the highest adherence group (under 10%). Target uric acid achievement dropped to 45% in poor adherers versus nearly 88% in the most consistent ones.7Rheumatology. Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study The benefits of allopurinol are cumulative, and it can take two or more years of sustained treatment before you really notice fewer flares and improved quality of life.8PubMed Central. Reasons for discontinuing urate-lowering treatment in community-dwelling adults with gout: results of a primary care-based cross-sectional study Patience pays off.
Genetic Testing Before You Start
A gene variant called HLA-B*5801 substantially increases the risk of severe skin reactions to allopurinol, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These are rare but can be life-threatening. The variant is found in roughly 6 to 15% of people in Southeast Asian and Han Chinese populations but is much less common in European and Japanese populations, where it appears in under 1% of people.9PLoS ONE. Cost-Effectiveness Analysis of HLA-B*5801 Testing in Preventing Allopurinol-Induced SJS/TEN in Thai Population
A meta-analysis found that in Korean, Thai, Sardinian Italian, and Han Chinese populations, testing for HLA-B*5801 catches the vast majority of people at risk, with pooled sensitivity around 97%. In European and Japanese populations, the test still identifies carriers but has lower sensitivity of about 50 to 60%.10PubMed. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis The American College of Rheumatology now recommends HLA-B*5801 testing for all patients before starting allopurinol, regardless of ethnicity. If you test positive, allopurinol should not be used, and an alternative like febuxostat is typically prescribed instead.
Hypersensitivity and Other Side Effects
Most people tolerate allopurinol well, but the side effects that do occur range from mild to very serious. Common mild effects include skin rash, stomach upset, and occasional changes in liver function tests. Allopurinol hypersensitivity syndrome is the reaction everyone wants to avoid. It involves a severe rash, fever, organ damage (often kidney and liver), and can be fatal. A large population-based study in Taiwan found that risk factors for this reaction include being female, being 60 or older, starting at a dose above 100 mg daily, having kidney or cardiovascular disease, and being treated for elevated uric acid levels without actual gout symptoms.2JAMA Internal Medicine. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan
That last point is worth lingering on: using allopurinol for asymptomatic hyperuricemia (a high uric acid reading without gout symptoms) combined with kidney or heart disease was associated with significantly higher odds of developing the hypersensitivity reaction and of dying from it. This is one reason many guidelines advise against treating elevated uric acid numbers alone when a person has never had gout.
Drug Interactions to Know About
The interaction between allopurinol and azathioprine is one of the most dangerous in clinical medicine and is worth understanding if you take both. Azathioprine, an immunosuppressant used after organ transplants and in autoimmune conditions, relies on xanthine oxidase to break down some of its metabolites into inactive forms. Because allopurinol blocks that same enzyme, the active metabolites of azathioprine build up, leading to severe bone marrow suppression: dangerously low white blood cell counts, anemia, and sometimes pancytopenia.11PubMed Central. Pancytopenia caused by allopurinol and azathioprine interaction in a heart transplant patient: a case report In reported cases, this complication typically showed up four to six weeks after the combination was started, and recovery followed once one of the drugs was stopped.12PubMed. Azathioprine and allopurinol: a potentially dangerous combination If both drugs are truly needed, the azathioprine dose must be cut drastically and blood counts monitored closely.
Furosemide, a common diuretic (water pill), also interacts with allopurinol, though less dramatically. Research suggests that furosemide interferes with one of the ways allopurinol suppresses uric acid production, meaning patients on furosemide may need higher allopurinol doses to reach target.13PubMed. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment Since diuretics are a common trigger for gout in the first place, this interaction comes up frequently in practice. Other notable interactions include warfarin (allopurinol can increase its blood-thinning effect) and certain antibiotics like ampicillin, which may cause rashes more frequently when combined with allopurinol.
Kidney Disease and Dose Adjustments
Allopurinol and kidney disease have a complicated relationship. The kidneys clear oxypurinol, so impaired kidney function means oxypurinol sticks around longer and accumulates to higher levels. Decades ago, a widely cited set of dose-reduction guidelines recommended capping the dose based on kidney function, sometimes to as little as 100 mg every other day. The problem is that those restrictive doses often fail to bring uric acid to target, leaving gout undertreated.
More recent evidence supports a different approach: start low (100 mg daily or less, depending on how impaired kidney function is) but then titrate upward gradually to whatever dose achieves the uric acid target. Studies where the dose was titrated to effect showed more patients reaching target compared with studies using fixed, renally adjusted doses.14PubMed. Safety and efficacy of allopurinol in chronic kidney disease The starting dose is what matters most for safety; the maintenance dose can be raised with careful monitoring.15Exploration of Musculoskeletal Diseases. Safety and efficacy of gout treatments in people with renal impairment Still, the evidence base here is mostly observational, and individual monitoring of kidney function and for signs of hypersensitivity remains essential.
Cardiovascular Safety Compared With Febuxostat
If your doctor has mentioned febuxostat as an alternative to allopurinol, you may have heard concerns about heart safety. A large trial known as CARES found that febuxostat and allopurinol had similar rates of major cardiovascular events overall, but cardiovascular death and all-cause death were higher in the febuxostat group.16PubMed. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout A subsequent European trial, FAST, reached a more reassuring result for febuxostat when looking only at patients who actually stayed on treatment, finding it was not inferior to allopurinol.17The Lancet. Cardiovascular safety of febuxostat or allopurinol in patients with gout A meta-analysis of Asian cohort studies found that febuxostat users had a modestly higher risk of acute coronary syndrome and atrial fibrillation compared with allopurinol users.18PubMed Central. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis
The practical takeaway is that allopurinol has a favorable cardiovascular safety profile. For most patients, it remains the first-line choice. Febuxostat is generally reserved for people who cannot tolerate allopurinol or who carry HLA-B*5801.
Pregnancy and Allopurinol
Allopurinol’s safety during pregnancy is poorly understood. Animal studies have shown species-specific reproductive toxicity, and a small number of human case reports have raised concern about a possible pattern of birth defects, though the evidence for causation is weak.19PubMed. The teratogenicity of allopurinol: A comprehensive review of animal and human studies A more recent multicentre study and systematic review pooled data on over 100 allopurinol-exposed pregnancies and found congenital anomalies in about 8% of live births overall, with a lower rate of roughly 2.6% in a subgroup of mothers with inflammatory bowel disease who were on low-dose allopurinol.20PubMed. Multicentre study and systematic review: Allopurinol exposure during pregnancy
The numbers are hard to interpret without large controlled studies. Some small case series have reported entirely normal outcomes.21PubMed Central. Allopurinol use in pregnancy in three women with inflammatory bowel disease: safety and outcomes: a case series In gout treatment, allopurinol is typically stopped before conception or as soon as pregnancy is confirmed. In inflammatory bowel disease, where allopurinol is sometimes combined with low-dose azathioprine to optimize therapy, the decision is harder and involves weighing the risks of active disease against the uncertain risks of the drug. This is a conversation for a specialist, not a general guideline.
Alcohol and Diet While on Allopurinol
You do not need to follow a severely restricted diet while taking allopurinol, but some choices help the drug do its job. Alcohol is the most relevant dietary factor. It raises uric acid levels, and episodes of heavy drinking are a well-known trigger for gout flares. An internet-based case-crossover study found that allopurinol use mitigated some of alcohol’s gout-triggering effects, but that does not mean alcohol is harmless while on treatment.22PubMed Central. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study Beer and spirits tend to be worse offenders than wine. Moderate consumption is unlikely to completely derail treatment, but heavy drinking can overwhelm the drug’s ability to keep uric acid low.
Staying well hydrated supports kidney function and helps with uric acid excretion. High-purine foods like organ meats, shellfish, and certain game meats still contribute to uric acid production, and limiting them is sensible even on allopurinol. That said, the point of drug therapy is to give you some dietary flexibility that lifestyle changes alone cannot provide. Allopurinol is powerful enough that most people on an adequate dose do not need to obsessively police every meal.
Uses Beyond Gout
Most people encounter allopurinol as a gout drug, but it plays an important role in cancer care as well. When tumor cells are destroyed rapidly by chemotherapy, they release large amounts of purines that the body converts into uric acid. This surge, called tumor lysis syndrome, can overwhelm the kidneys. Allopurinol is used prophylactically in patients at low to intermediate risk to prevent this uric acid spike.23Haematologica. Consensus conference on the management of tumor lysis syndrome It blocks the conversion of purines into uric acid, preventing crystal formation in the kidney tubules.24PubMed Central. Tumor lysis syndrome in childhood malignancies For higher-risk patients, a different drug called rasburicase is preferred because it breaks down uric acid that has already formed, rather than just preventing new production.25PubMed Central. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase The dosing and duration of allopurinol in this setting differ from gout treatment: it is typically started a day or two before chemotherapy and continued for a short course rather than indefinitely.
Liver Function and Monitoring
Mild elevations in liver enzymes show up occasionally in people taking allopurinol. Reviews comparing allopurinol with febuxostat across randomized trials have found that both drugs produce similar rates of abnormal liver function tests, and most of these elevations are mild to moderate. Occasionally they lead to stopping the drug, but serious liver injury from allopurinol alone is uncommon. Routine blood work when you are starting or adjusting the dose typically includes liver function along with kidney function and uric acid levels. If you already have liver disease, your doctor will want closer monitoring, but allopurinol is not automatically off the table.